# Apatinib Combined with Temozolomide and Etoposide Capsules in the Treatment of Recurrent Medulloblastoma in Children

> **NCT04501718** · PHASE2 · RECRUITING · sponsor: **Beijing Sanbo Brain Hospital** · enrollment: 44 (estimated)

## Conditions studied

- Recurrent Medulloblastoma

## Interventions

- **DRUG:** Apatinib Combined With Temozolomide and Etoposide Capsules

## Key facts

- **NCT ID:** NCT04501718
- **Lead sponsor:** Beijing Sanbo Brain Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2020-10-28
- **Primary completion:** 2025-08-31
- **Final completion:** 2025-08-31
- **Target enrollment:** 44 (ESTIMATED)
- **Last updated:** 2024-10-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04501718

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04501718, "Apatinib Combined with Temozolomide and Etoposide Capsules in the Treatment of Recurrent Medulloblastoma in Children". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04501718. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*